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Abstract. In cancer diagnosis, classification of the different tumor types is of great
importance. An accurate prediction of different tumor types provides better treatment
and may minimize the negative impact of incorrectly targeted toxic or aggressive treat-
ments. Moreover, the correct prediction of cancer types using non-invasive information
–e.g. 1H-MRS data– could avoid patients to suffer collateral problems derived from
exploration techniques that require surgery. A Feature Selection Algorithm specially
designed to be use in 1H-MRS Proton Magnetic Resonance Spectroscopy data of brain
tumors is presented. It takes advantage of a highly distinctive aspect in this data: some
metabolite levels are notoriously different between types of tumors. Experimental read-
ings on an international dataset show highly competitive models in terms of accuracy,
complexity and medical interpretability.
1 Introduction
Proton (or Hydrogen) Magnetic Resonance Spectroscopy (1H-MRS) has been used
extensively in biochemistry for in vitro chemical analysis of small samples for several
years. As a technique for in vivo sampling of biological tissue, it provides a quan-
tified biochemical fingerprint of metabolite concentrations [1]. 1H-MRS data has the
appearance of a plot of peaks along the x-axis, with the peak position depending on the
resonant frequency of the associated metabolite [2]. An example of a 1H-MRS dataset
is shown in Fig. 1.
Nowadays, 1H-MRS has been proven its value as a powerful tool in the clinical as-
sessment of several pathologic conditions -e.g. epilepsy, multiple sclerosis, cancer– and
specially in neurological affections [3, 4]. Framed as a minimal invasive technique, its
application in brain tumor oncological diagnosis carries tremendous benefits to patients,
relieving them from complicated surgical procedures and minimizing trauma to normal
tissue surrounding the particular lesion or other vital elements.
The use of systematic approaches based on 1H-MRS data for the diagnosis and grad-
ing of adult brain tumors is subject of an extensive scientific research. One of these
growing approaches takes as backbone well-established machine learning techniques
to develop predictive models able to discern between several classes of brain tumors
[5, 6, 7]. This particular task is quite challenging, mainly because of the high dimen-
sionality and relatively low number of observations. Therefore, the use of dimensional-
ity reduction (and, in particular, feature selection) methods becomes an option in order
to present low complexity and interpretable models to oncologists.
In this study, an ad hoc feature selection (FS) algorithm is used to generate relevant
subsets of spectral frequencies (considered as features). The developed algorithm takes
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Figure 1: An example of a long time of echo 1H-MRS dataset. Some of the metabolites visible in this
kind of spectrum are the Choline, which is a combination of multiple metabolites and is elevated in all
brain tumors; the Creatine, a marker of oxidative metabolism of cells; the N-acetylaspartate, a neuronal
density marker; the Lipids, seen in condition of necrosis.
advantage of a distinctive aspect shown in typical 1H-MRS readings: some metabolite
levels are quite different between types of tumors. Bootstrap resampling is used to
reduce sampling variability and obtain more stable readings. We report experimental
work in which a small subset of frequencies is able to offer a highly accurate predictive
model (a linear classifier). The proposed solution is also discussed in terms of visual
appearance and interpretation of the obtained metabolites.
2 Literature review
First attempts using 1H-MRS data in assessing human brain tumors in vivo are back
to [3]. It was found that spectra differ significantly from normal brain spectra and be-
tween tumors by detecting the presence/absence of different metabolites. Even though
no machine learning (ML) analysis of spectra was done in establishing these differ-
ences, it was concluded that 1H-MRS spectroscopy may help to differentiate tumors for
diagnostic and therapeutic purposes, limiting the need for invasive and risky diagnostic
procedures such as biopsies.
At this point, ML techniques arise in order to automate the classification tasks. Arti-
ficial neural networks (e.g. [8, 9]) and linear discriminant analysis (LDA) (e.g. [5, 10])
are commonly used methods. Later studies perform dimensionality reduction, either
considering the peak signals, ratios between peak signals or feature extraction based
in principal component analysis or independent component analysis [11, 12, 13]. First
studies in performing an explicit feature selection process have used simple well-known
search algorithms to select subset of spectral points, such as forward selection [14], the
Fisher criterion or the Relief feature weighing algorithm [15]. More recent works in FS
properly speaking are found in [7, 16, 17, 18], which address a multi-class problem on
the same dataset analyzed in this work. The dominant techniques are single-layer neu-
ral networks or classical feature selection search algorithms wrapping several classifiers,
among which LDA usually yields the best predictive models.
3 Class-Separability Feature Selection
It is known that metabolites (spectral points) in 1H-MRS data present notorious dif-
ferences among tumors. For example, theoretically, meningiomas do not contain N-
acetyl aspartate (NAA) and present the choline (CHO) elevated (up to 300 times the
normal reading). Metastases present a moderate reduction in NAA and a decreased
creatine (CR) signal. Lipid levels located at 1.3 ppm are mainly arisen in high-grade
brain malignancies. These fingerprints that distinguish each tumor could lead us to try
to establish a measure of physical distance between kinds of tumors that expresses the
separability between classes. A very simple choice is taken in this study for this mea-
sure: the distance (absolute difference) between the median profiles across the different
pairs of classes (tumour types).
Taking as primary data a bootstrap distribution, averaged estimations of such dis-
tances from the original 1H-MRS data can be computed. The bootstrap distribution of
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these values offers other quantities of interest (such as the variance), but these are not
used here. The median is used (instead of the mean) with the goal of reducing the influ-
ence of possible abnormally high (or low) profiles. If used, these profiles could signal a
fake high separability.
The separability degree of metabolites with respect to each tumor is then assessed
by the cumulative differences between pairs of elements –i.e. between tumors– thereby
obtaining a new feature vector based on distances. It is hypothesized that the direction
that best separates tumors taking as basis the metabolites that present abnormal values
is partly expressed in this vector.
Algorithm 1: CSFS Class Separability Feature Selection
input : set of bootstrap resamples S1; : : : ; SB ; L classifier
output: BSS: Best Spectral Subset
foreach sample b 2 f1; : : : ; Bg do1
foreach spectral point s do2
foreach class c do3
m[b; s; c] median of spectral point s for class c in Sb4
m[s; c] = 1
B
BX
b=1
m[b; s; c]
5
foreach spectral point s do6
foreach pair of different classes (ci; cj) do7
DS[s] DS[s] + j m[s; i]  m[s; j]j8
SortDS in decreasing order9
BSS  ?10
Jbest 011
repeat12
***Forward Stage***13
for i 2 f1; : : : ; jDSjg do14
foreach sample b 2 f1; : : : ; Bg do15
J [b] L(Sb; S n Sb; BSS [ fDS[i]g)16
J  1
B
BX
b=1
J [b]
17
if J > Jbest then18
Jbest J19
BSS  BSS [DS[i]20
***Backward Stage***21
repeat22
for j 2 f1; : : : ; jBSSjg do23
foreach sample b 2 B do24
J [b] L(Sb; S n Sb; BSS n fBSS[j]g)25
J  1
B
BX
b=1
J [b]
26
if J  Jbest then27
Jbest J28
BSS  BSS n fBSS[j]g29
until no more Backward improvement30
until no more Forward or Backward improvement31
To capture the aforementioned behavior, the CSFS algorithm (which briefs for Class-
Separability Feature Selection) is designed and outlined in Algorithm 1. Taking as
primary data the bootstrap distribution from the original 1H-MRS data, stable distance
estimations are computed, and a centroid m for every spectral point within each tumor
is computed (lines 1-5) and a vector of centroids is generated by averaging them over
the B bootstrap samples. In order to asses the separability degree of metabolites with
respect to each tumor, the cumulative difference between pairs of elements –i.e. between
tumors– is computed (lines 7-9), obtaining a new feature vector based on distances
named DS (sorted in decreasing order in line 9). Hence, the CSFS Algorithm takes
advantage of abnormal presence of certain metabolites that allows to identify specific
tumors. As a consequence, its operation is guided by the ones that present a higher
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separability degree in a ranked list.
Once this evaluation is complete, a combined Forward-Backward search strategy is
implemented, fed by the DS vector as follows: a Forward step is given taking the first
element in the ranked list DS (lines 13-20) and its average performance is evaluated
against the bootstrap resamples via a user-defined classifier L. Taking into account
that the 1H-MRS data could be considered as a spatial series, in the sense that spectral
points are ordered in the metabolic spectrum, it is likely that contiguous spectral points
offer similar separability values and hence are found indexed in consecutive positions
in DS. For instance, the Creatine peak, located at 3.03 ppm in the spectrum will have a
separability value similar to the 3.01 ppm spectral point, which almost defines the same
metabolite. In order to avoid the inclusion of redundant features, a Backward stage takes
place right after every single Forward stage, with the difference that this latter process
is executed as much as necessary, and until no improvement is achieved (lines 21-30).
4 Experimental work
In this section, the experimental conditions are outlined. The 1H-MRS dataset em-
ployed is described jointly with the brain pathologies involved. Several well known
classifiers are used to measure the subsets performance as long as statistical tests to
asses uncertainty about comparisons between models.
4.1 Datasets
An essential variable in the acquisition of 1H-MRS spectra is the choice of echo
time. With short times of echo (around 20 ms), larger numbers of metabolites are
detected (myoinositol, glutamate, glutamine), but it is more likely that peak superim-
position will occur, causing difficulty in spectroscopic curve interpretation. By using
long times of echo (more than 135 ms), most metabolites in the brain are lost (except
that of choline, creatine, NAA and lactate), but with better definition of peaks, thereby
facilitating graphic analysis[19]. There are a few studies comparing the classification
potential of the two types of spectra (see e.g. [10], [6]). These works seem to give a
slight advantage to using short time of echo information or else suggest a combination
of both types of spectra.
The targeted 1H-MRS data is drawn from a database belonging to the International
Network for Pattern Recognition of tumors Using Magnetic Resonance (INTERPRET).
An European research project aimed to develop systematic tools to enable radiolo-
gists and other clinicians without special knowledge or expertise to diagnose and grade
brain tumors routinely using magnetic resonance spectroscopy [20]. The dataset is con-
structed by single voxel 1H-MR spectra acquired in vivo from brain tumor patients in
two configurations: Long Time of Echo (PRESS 135-144 ms), named LTE, and Short
Time of Echo (PRESS 30-32 ms), named STE. Brain pathologies that conform both
configurations are distributed as following:
 LTE: 195 observations, including 55 meningiomas, 78 glioblastomas, 31 metas-
tases, 20 astrocytomas grade II, 6 oligoastrocytomas grade II and 5 oligoden-
drogliomas grade II.
 STE: 217 observations, including 58 meningiomas, 86 glioblastomas, 38 metas-
tases, 22 astrocytomas grade II, 6 oligoastrocytomas grade II, and 7 oligoden-
drogliomas grade II.
Both spectra were grouped into three super-classes: high-grade malignant tumors
(metastases and glioblastomas), low-grade gliomas (astrocytomas, oligodendrogliomas
and oligoastrocytomas) and meningiomas. A third configuration was prepared in order
to explore the discriminative power of the merged LTE and STE data resulting in 195
common observations of the two previous datasets, and labeled as LSTE.
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Table 1: CSFS Feature selection results and final performance. The number in square brackets is the final
Best Spectral Subset (BSS) size. The right number is the averaged 10x10 CV accuracy in the original
(continuous) 1H-MRS datasets.
NN LDC QDC LR lSVM rSVM
LTE [11] 89.70 [15] 93.51 [9] 89.09 [7] 91.48 [9] 91.82 [10] 93.88
STE [8] 92.21 [16] 93.34 [6] 87.40 [8] 90.48 [12] 93.14 [8] 94.48
LSTE [17] 96.14 [26] 98.27 [8] 92.83 [7] 92.07 [14] 94.83 [12] 94.77
Table 2: Spectral points selected in best solutions –see bold faced models in Table 1.
Best model ppm
LTE-rSVM 3.74, 2.94, 2.54, 2.35, 1.72, 1.61, 1.25, 1.10, 0.72, 0.66
STE-rSVM 3.81, 3.64, 3.51, 3.07, 2.44, 2.43, 2.37, 2.27
LSTE-LDC L3.81, L3.66, L3.11, L3.07, L2.98, L2.90, L2.75
L2.69, L2.29, L2.18, L1.86, L1.55, L0.83, L0.62
S4.19, S3.81, S3.66, S3.53, S3.49, S2.29, S2.25
S1.32, S1.13, S1.04, S0.70, S0.66
4.2 Experimental settings
The original 1H-MRS datasets S = fLTE; STE;LSTEg were used to generate
B = 1; 000 bootstrap samples S1; : : : ; SB that play the role of training sets in the
feature selection process: each classifier L is developed on each Sb resample and its
performance is assessed on the test sample S n Sb, and averaged across the B boot-
strap samples. Once the final BSS is obtained, the final performance is assessed using
10 times 10-fold Cross Validation (10x10 CV) using the original (not discretized) 1H-
MRS datasets: the nearest-neighbor technique (NN), the Logistic Regression (LR), a
Linear and Quadratic Discriminant classifier (LDC, QDC), Support Vector Machine
with linear kernel (lSVM) and parameter C (regularization constant) and Support Vec-
tor Machine with radial kernel (rSVM) and parameters C and 2 (amount of smoothing
in the kernel)1. The Wilcoxon signed rank test is applied in order to evaluate a possible
statistical significance in the performance of the different models.
5 Discussion of the results
In Table 1, the CSFS feature selection process is displayed. Among the classifiers in
LTE data, the rSVM yields the best performance, giving a 93.88% of accuracy with only
10 spectral points; quite close comes LDC at second position with a very similar figure
at 93.51% accuracy and 15 spectral points. Precisely, the Wilcoxon signed rank test at
95% level (p-value< 0.05) show significant results comparing the rSVM results against
all the others, except with LDC (p-value is 0.160). The STE data experiments show
exactly the same behavior, but offering higher readings. The rSVM reaches 94.48%
with only 8 spectral points; its first place in this data configuration is supported against
all the rest (all p-values are lower than 0.002).
The LSTE experiments render the best results in all cases. The best final performance
corresponds to LDC with 98.27% of accuracy using 26 spectral points. Wilcoxon’s test
p-values give statistical confirmation to this competitive model against all the others.
The LSTE-LDC model yields one of the best reported values using this data set with
this particular configuration of super-classes –see, e.g., [16, 6, 11, 12, 21]. Another
recent work reports a very similar final performance, claiming a 98.46% accuracy using
5x5 CV resampling (instead of 10x10 CV as in this study) using 18 spectral points
by means of a single-layer Perceptron neural network [18]. This is a very attractive
solution since it uses a lesser number of spectral points. However, the developed LSTE-
LDC solution uses a classifier that requires no parameter tuning in training phase and
1C and 2 are optimized via a grid search.
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is computationally cheaper. It is also interesting to note that both methods (LDC and
the neural network) offer linear decision boundaries. The spectral points selected in the
best solutions are displayed in Table 2 in terms of their ppm values. The final selected
feature subset of the best LSTE-LDC model as positioned in the whole spectrum is
displayed in Fig. 2. In order to better appreciate the solution in its spectral environment,
the mean spectra for the three super-classes are added to the plot.
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Figure 2: Best Spectral Subset from LSTE-LDC model as positioned in the whole spectrum.
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Figure 3: Projection of the dataset (using the final selected feature subset of the best LSTE-LDC model)
onto the first two eigenvectors of the scatter matrices as coordinate system. Circles represent low-grade
gliomas; filled squares high-grade malignant tumors and stars meningiomas.
5.1 Data visualization
Data visualization in a low-dimensional space may become extremely important to
radiologists, helping them to gain insights into what undoubtedly is a complex domain.
We use in this work a method based on the decomposition of the scatter matrix with
the property of maximizing the separation between the projections of compact groups
of tumor classes –see [24]. Such visualization is illustrated in Fig. 3. These are scatter
plots of 3-D projections of the three classes (using the first three eigenvectors of the
scatter matrices). It is seen that the three supper-classes are notoriously well separated.
5.2 Metabolic interpretation
The metabolites detected and their known biological function are listed in Table 3. It
is necessary to clarify that some metabolites posses resonances at different positions in
the spectrum –e.g. Threonine or Valine. For a complete description refer to the source
at [22]. The Glycerol-phosphocholine-choline and the Ethanolamine both deserve a
particular comment, given that they show an interesting behavior in appearing in the
two parts of the LSTE dataset, the Long and the Short times of echo. Looking for
common metabolites with [18] (previously discussed in literature review) the following
were found: Alanine, Myo-Inositol, Taurine, Choline, Glutamate and Glutamine.
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Table 3: Metabolic interpretation in best models. For reading purposes the first group on each metabolite
labeled. Prefix L, S signal which part belong to and all values are ppm expressed.
Metabolite Biological interpretation
Glycerol-
phosphocholine-
choline
An end product of membrane phospholipid degradation and increased concentrations have been
associated with cerebral ischemia, seizures and traumatic brain injury.
fL3.66 S3.66g
Ethanolamine Increased levels of this metabolite has been observed in ischemic brain tissue of rats and gerbils.
fL3.81 S3.81g
Glutathione-
glutamate
An anti-oxidant, essential for maintaining normal red-cell structure. Altered levels have been
reported in Parkinsons’s disease and other neurodegenerative diseases.
fL2.18g
Alanine A nonessential amino acid that has been observed in increased levels in meningiomas.
fL1.55g
Threonine A large neutral amino acid essential to the diet. fS4.19 S1.32g
Valine An essential amino acid necessary for protein synthesis observed in brain abscesses.
fS2.25 S1.04g
Phenylalanine An aromatic amino acid that presents elevated readings in phenylketonuria, an abnormal pheny-
lalanine metabolization. fL3.11 L3.07g
Glutathione-
cysteine
See Glutathione-glutamate. fL2.98 L2.90g
Aspartate An excitatory amino acid that performs as a neurotoxin in elevated concentrations [23]. fL2.75g
NAA-Aspartate A free amino acid whose function is poorly understood, but is is commonly believed to provide a
marker of neuronal density. fL2.69g
GABA A primary inhibitory neurotransmitter whose altered concentrations are associated with neurolog-
ical disorders. fL2.29 L1.86 S2.29g
Myo-inositol Its function is not enough understood, although it is believed to be a requirement in cell growth.
Altered levels have been linked with Alzheimer’s disease, hepatic encephalopathy and brain injury.
fS3.53g
Choline A combination of multiple metabolites and is elevated in all brain tumors. It is required for the
synthesis of neurotransmitters constituents of membranes. fS3.49g
Not identified fL0.83 L0.62 S1.13 S0.70 S0.66g.
6 Conclusions
A feature selection algorithm has been introduced as a strategy to select subsets of
spectral points from 1H-MRS spectral data of brain tumors. The proposed algorithm
takes advantage of the differential presence of certain metabolites that could allow to
identify a specific tumor. It also accounts for possible redundancies introduced in the
selected subsets of spectral points that could be derived from this approach. The final
model obtained is considerable competitive in terms of accuracy, complexity of the
algorithmic process needed to obtain it, and medical interpretability with respect to
other solutions in the literature.
In this vein, it should be noted that, although a “best” subset of spectral points could
certainly exist to solve the task at hand, it is extremely unlikely that it is found by
a search process, for two reasons. The first reason is an algorithmic one, given the
exponential size of the set of all possible solutions. The second reason has to do with
statistical significance (all computations with finite samples are uncertain and, to some
extent, unreliable) and to model assessment (the classifiers are prone to overfit small
datasets). This is the reason why we complement the solution with the interpretation and
visualization parts, although the expertise provided by radiologists and other clinicians
is invaluable for a complete evaluation.
This study has also confirmed that the LSTE combination renders better subsets in
classification accuracy terms than the other two datasets alone. Also, the results suggest
that linear models are among the best suited for the task, but only after a dimensionality
reduction process. In addition, most of the identified metabolites are positively defined
by the medical literature and some concordances are found with successful recent ma-
chine learning works.
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